{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:37:57Z","timestamp":1790656677732,"version":"4.1.0"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T00:00:00Z","timestamp":1540771200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s11899-018-0474-6","type":"journal-article","created":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T02:31:29Z","timestamp":1540780289000},"page":"435-445","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Chronic Myeloid Leukemia: Beyond BCR-ABL1"],"prefix":"10.1007","volume":"13","author":[{"given":"Ting","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,29]]},"reference":[{"issue":"3","key":"474_CR1","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","volume":"5","author":"R Ren","year":"2005","unstructured":"Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5(3):172\u201383.","journal-title":"Nat Rev Cancer"},{"key":"474_CR2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1182\/asheducation-2013.1.189","volume":"2013","author":"W Ahmed","year":"2013","unstructured":"Ahmed W, Van Etten RA. Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond. Hematology Am Soc Hematol Educ Program. 2013;2013:189\u2013200.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"474_CR3","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1158\/1078-0432.CCR-10-1613","volume":"18","author":"D Cilloni","year":"2012","unstructured":"Cilloni D, Saglio G. Molecular pathways: BCR-ABL. Clin Cancer Res. 2012;18(4):930\u20137.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"474_CR4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.trsl.2006.07.002","volume":"148","author":"HG Goh","year":"2006","unstructured":"Goh HG, Hwang JY, Kim SH, Lee YH, Kim YL, Kim DW. Comprehensive analysis of BCR-ABL transcript types in Korean CML patients using a newly developed multiplex RT-PCR. Transl Res. 2006;148(5):249\u201356.","journal-title":"Transl Res"},{"issue":"3","key":"474_CR5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/ijlh.12616","volume":"39","author":"AK Arun","year":"2017","unstructured":"Arun AK, Senthamizhselvi A, Mani S, Vinodhini K, Janet NB, Lakshmi KM, et al. Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients. Int J Lab Hematol. 2017;39(3):235\u201342.","journal-title":"Int J Lab Hematol"},{"issue":"6","key":"474_CR6","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","volume":"7","author":"JV Melo","year":"2007","unstructured":"Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007;7(6):441\u201353.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"474_CR7","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1038\/bcj.2017.62","volume":"7","author":"Z Gong","year":"2017","unstructured":"Gong Z, Medeiros LJ, Cortes JE, Zheng L, Khoury JD, Wang W, et al. Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia. Blood Cancer J. 2017;7(7):e583.","journal-title":"Blood Cancer J"},{"issue":"9","key":"474_CR8","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1084\/jem.189.9.1399","volume":"189","author":"S Li","year":"1999","unstructured":"Li S, Ilaria RL Jr, Million RP, Daley GQ, van Etten R. The P190, P210, and P230 forms of the BCR\/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med. 1999;189(9):1399\u2013412.","journal-title":"J Exp Med"},{"issue":"6","key":"474_CR9","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nm1253","volume":"11","author":"A Castor","year":"2005","unstructured":"Castor A, Nilsson L, \u00c5strand-Grundstr\u00f6m I, Buitenhuis M, Ramirez C, Anderson K, et al. Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med. 2005;11(6):630\u20137.","journal-title":"Nat Med"},{"issue":"3","key":"474_CR10","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1128\/MCB.9.3.1263","volume":"9","author":"TG Lugo","year":"1989","unstructured":"Lugo TG, Witte ON. The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc. Mol Cell Biol. 1989;9(3):1263\u201370.","journal-title":"Mol Cell Biol"},{"issue":"9","key":"474_CR11","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.1128\/MCB.11.9.4710","volume":"11","author":"M Kelliher","year":"1991","unstructured":"Kelliher M, Knott A, McLaughlin J, Witte ON, Rosenberg N. Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR\/ABL oncogene. Mol Cell Biol. 1991;11(9):4710\u20136.","journal-title":"Mol Cell Biol"},{"issue":"12","key":"474_CR12","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1182\/blood.V86.12.4603.bloodjournal86124603","volume":"86","author":"JW Voncken","year":"1995","unstructured":"Voncken JW, Kaartinen V, Pattengale PK, Germeraad WT, Groffen J, Heisterkamp N. BCR\/ABL P210 and P190 cause distinct leukemia in transgenic mice. Blood. 1995;86(12):4603\u201311.","journal-title":"Blood"},{"issue":"7","key":"474_CR13","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/leu.2017.36","volume":"31","author":"S Reckel","year":"2017","unstructured":"Reckel S, Hamelin R, Georgeon S, Armand F, Jolliet Q, Chiappe D, et al. Differential signaling networks of Bcr-Abl p210 and p190 kinases in leukemia cells defined by functional proteomics. Leukemia. 2017;31(7):1502\u201312.","journal-title":"Leukemia"},{"issue":"5232","key":"474_CR14","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1126\/science.7569929","volume":"269","author":"NN Danial","year":"1995","unstructured":"Danial NN, Pernis A, Rothman PB. Jak-STAT signaling induced by the v-abl oncogene. Science. 1995;269(5232):1875\u20137.","journal-title":"Science"},{"issue":"49","key":"474_CR15","doi-asserted-by":"crossref","first-page":"31704","DOI":"10.1074\/jbc.271.49.31704","volume":"271","author":"RL Ilaria Jr","year":"1996","unstructured":"Ilaria RL Jr, van Etten RA. P210 and P190BCR\/ABL induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem. 1996;271(49):31704\u201310.","journal-title":"J Biol Chem"},{"issue":"3","key":"474_CR16","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S1074-7613(00)80439-2","volume":"4","author":"MH Kaplan","year":"1996","unstructured":"Kaplan MH, Schindler U, Smiley ST, Grusby MJ. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity. 1996;4(3):313\u20139.","journal-title":"Immunity"},{"issue":"2","key":"474_CR17","first-page":"81","volume":"32","author":"GD Telegeev","year":"2010","unstructured":"Telegeev GD, Dubrovska AN, Nadgorna VA, Dybkov MV, Zavelevich MP, Maliuta SS, et al. Immunocytochemical study of Bcr and Bcr-Abl localization in K562 cells. Exp Oncol. 2010;32(2):81\u20133.","journal-title":"Exp Oncol"},{"issue":"6","key":"474_CR18","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1182\/blood.V96.6.2226","volume":"96","author":"N Heisterkamp","year":"2000","unstructured":"Heisterkamp N, Voncken JW, Senadheera D, Gonzalez-Gomez I, Reichert A, Haataja L, et al. Reduced oncogenicity of p190 Bcr\/Abl F-actin-binding domain mutants. Blood. 2000;96(6):2226\u201332.","journal-title":"Blood"},{"issue":"4","key":"474_CR19","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.molcel.2005.06.030","volume":"19","author":"O Hantschel","year":"2005","unstructured":"Hantschel O, Wiesner S, G\u00fcttler T, Mackereth CD, Rix LL, Mikes Z, et al. Structural basis for the cytoskeletal association of Bcr-Abl\/c-Abl. Mol Cell. 2005;19(4):461\u201373.","journal-title":"Mol Cell"},{"key":"474_CR20","doi-asserted-by":"crossref","unstructured":"Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel). 2017;9(5):52.","DOI":"10.3390\/cancers9050052"},{"key":"474_CR21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1478-811X-7-13","volume":"7","author":"RB Birge","year":"2009","unstructured":"Birge RB, et al. Crk and CrkL adaptor proteins: networks for physiological and pathological signaling. Cell Commun Signal. 2009;7:13.","journal-title":"Cell Commun Signal"},{"issue":"2","key":"474_CR22","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1128\/MCB.11.2.1107","volume":"11","author":"L Varticovski","year":"1991","unstructured":"Varticovski L, Daley GQ, Jackson P, Baltimore D, Cantley LC. Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants. Mol Cell Biol. 1991;11(2):1107\u201313.","journal-title":"Mol Cell Biol"},{"issue":"5","key":"474_CR23","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1182\/blood.V88.5.1542.1542","volume":"88","author":"SK Jain","year":"1996","unstructured":"Jain SK, Susa M, Keeler ML, Carlesso N, Druker B, Varticovski L. PI 3-kinase activation in BCR\/abl-transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR\/abl. Blood. 1996;88(5):1542\u201350.","journal-title":"Blood"},{"issue":"2","key":"474_CR24","first-page":"247","volume":"13","author":"K Shuai","year":"1996","unstructured":"Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene. 1996;13(2):247\u201354.","journal-title":"Oncogene"},{"issue":"10","key":"474_CR25","first-page":"2791","volume":"62","author":"TJ Gaymes","year":"2002","unstructured":"Gaymes TJ, Mufti GJ, Rassool FV. Myeloid leukemias have increased activity of the nonhomologous end-joining pathway and concomitant DNA misrepair that is dependent on the Ku70\/86 heterodimer. Cancer Res. 2002;62(10):2791\u20137.","journal-title":"Cancer Res"},{"issue":"41","key":"474_CR26","doi-asserted-by":"crossref","first-page":"5826","DOI":"10.1038\/sj.onc.1204549","volume":"20","author":"RR Hoover","year":"2001","unstructured":"Hoover RR, Gerlach MJ, Koh EY, Daley GQ. Cooperative and redundant effects of STAT5 and Ras signaling in BCR\/ABL transformed hematopoietic cells. Oncogene. 2001;20(41):5826\u201335.","journal-title":"Oncogene"},{"issue":"12","key":"474_CR27","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1182\/blood-2004-05-1941","volume":"104","author":"MO Nowicki","year":"2004","unstructured":"Nowicki MO, Falinski R, Koptyra M, Slupianek A, Stoklosa T, Gloc E, et al. BCR\/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood. 2004;104(12):3746\u201353.","journal-title":"Blood"},{"issue":"5","key":"474_CR28","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1158\/1541-7786.MCR-10-0356","volume":"9","author":"M Albajar","year":"2011","unstructured":"Albajar M, Gomez-Casares MT, Llorca J, Mauleon I, Vaque JP, Acosta JC, et al. MYC in chronic myeloid leukemia: induction of aberrant DNA synthesis and association with poor response to imatinib. Mol Cancer Res. 2011;9(5):564\u201376.","journal-title":"Mol Cancer Res"},{"issue":"2","key":"474_CR29","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000046636","volume":"107","author":"B Johansson","year":"2002","unstructured":"\u2022\u2022 Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 2002;107(2):76\u201394 Comprehensive and elegant review of cytogenetic changes in CML in pre-TKI era.","journal-title":"Acta Haematol"},{"issue":"7","key":"474_CR30","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00277-012-1421-6","volume":"91","author":"Q Mu","year":"2012","unstructured":"Mu Q, Ma Q, Wang Y, Chen Z, Tong X, Chen FF, et al. Cytogenetic profile of 1,863 Ph\/BCR-ABL-positive chronic myelogenous leukemia patients from the Chinese population. Ann Hematol. 2012;91(7):1065\u201372.","journal-title":"Ann Hematol"},{"issue":"11","key":"474_CR31","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","volume":"103","author":"B Calabretta","year":"2004","unstructured":"Calabretta B, Perrotti D. The biology of CML blast crisis. Blood. 2004;103(11):4010\u201322.","journal-title":"Blood"},{"issue":"6","key":"474_CR32","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"\u2022\u2022 Baccarani M, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872\u201384 Updated recommendations for treatment and monitoring of CML.","journal-title":"Blood"},{"key":"474_CR33","first-page":"153","volume-title":"Cancer cytogenetics","author":"T Fioretos","year":"2016","unstructured":"Fioretos T. Chronic myeloid leukemia. In: Heim S, Mitelman F, editors. Cancer cytogenetics. Hoboken: Wiley; 2016. p. 153\u201374."},{"issue":"1","key":"474_CR34","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.leukres.2013.09.011","volume":"38","author":"S Soverini","year":"2014","unstructured":"Soverini S, Branford S, Nicolini FE, Talpaz M, Deininger MW, Martinelli G, et al. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res. 2014;38(1):10\u201320.","journal-title":"Leuk Res"},{"issue":"Suppl 2","key":"474_CR35","doi-asserted-by":"crossref","first-page":"S227","DOI":"10.1007\/s00277-015-2327-x","volume":"94","author":"B Hanfstein","year":"2015","unstructured":"Hanfstein B, Muller MC, Hochhaus A. Response-related predictors of survival in CML. Ann Hematol. 2015;94(Suppl 2):S227\u201339.","journal-title":"Ann Hematol"},{"issue":"27","key":"474_CR36","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1200\/JCO.2014.56.3908","volume":"32","author":"R Hehlmann","year":"2014","unstructured":"Hehlmann R, Hasford J, Pfirrmann M, Lauseker M, Sau\u00dfele S, Hochhaus A, et al. Reply to H. Kantarjian et al. J Clin Oncol. 2014;32(27):3078\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"474_CR37","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1038\/bcj.2017.4","volume":"7","author":"Z Chen","year":"2017","unstructured":"Chen Z, Medeiros LJ, Kantajian HM, Zheng L, Gong Z, Patel KP, et al. Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemia. Blood Cancer J. 2017;7(2):e521.","journal-title":"Blood Cancer J"},{"issue":"3","key":"474_CR38","doi-asserted-by":"crossref","first-page":"328","DOI":"10.4103\/ijmpo.ijmpo_115_17","volume":"38","author":"PK Chaitanya","year":"2017","unstructured":"Chaitanya PK, Kumar KA, Stalin B, Sadashivudu G, Srinivas ML. The role of mutation testing in patients with chronic myeloid leukemia in chronic phase after imatinib failure and their outcomes after treatment modification: single-institutional experience over 13\u00a0years. Indian J Med Paediatr Oncol. 2017;38(3):328\u201333.","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"2","key":"474_CR39","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/107327480901600204","volume":"16","author":"A Quintas-Cardama","year":"2009","unstructured":"Quintas-Cardama A, Kantarjian HM, Cortes JE. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control. 2009;16(2):122\u201331.","journal-title":"Cancer Control"},{"issue":"10","key":"474_CR40","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","volume":"20","author":"E Jabbour","year":"2006","unstructured":"Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O'Brien S, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia. 2006;20(10):1767\u201373.","journal-title":"Leukemia"},{"issue":"24","key":"474_CR41","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","volume":"12","author":"S Soverini","year":"2006","unstructured":"Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res. 2006;12(24):7374\u20139.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"474_CR42","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc3317","volume":"12","author":"T O'Hare","year":"2012","unstructured":"O'Hare T, Zabriskie MS, Eiring AM, Deininger MW. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer. 2012;12(8):513\u201326.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"474_CR43","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","volume":"8","author":"JF Apperley","year":"2007","unstructured":"Apperley JF. Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007;8(11):1018\u201329.","journal-title":"Lancet Oncol"},{"issue":"17","key":"474_CR44","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood-2008-10-183665","volume":"116","author":"DW Sherbenou","year":"2010","unstructured":"Sherbenou DW, Hantschel O, Kaupe I, Willis S, Bumm T, Turaga LP, et al. BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood. 2010;116(17):3278\u201385.","journal-title":"Blood"},{"issue":"19","key":"474_CR45","doi-asserted-by":"crossref","first-page":"8912","DOI":"10.1158\/0008-5472.CAN-05-0076","volume":"65","author":"DJ Barnes","year":"2005","unstructured":"Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong ASM, Wong A, et al. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res. 2005;65(19):8912\u20139.","journal-title":"Cancer Res"},{"issue":"5","key":"474_CR46","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2404609","volume":"21","author":"X Jiang","year":"2007","unstructured":"Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, Eaves A, et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia. 2007;21(5):926\u201335.","journal-title":"Leukemia"},{"issue":"12","key":"474_CR47","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","volume":"104","author":"J Thomas","year":"2004","unstructured":"Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood. 2004;104(12):3739\u201345.","journal-title":"Blood"},{"issue":"6","key":"474_CR48","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","volume":"119","author":"A Hamilton","year":"2012","unstructured":"Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S, Allan EK, et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood. 2012;119(6):1501\u201310.","journal-title":"Blood"},{"issue":"1","key":"474_CR49","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1172\/JCI43605","volume":"121","author":"A Perl","year":"2011","unstructured":"Perl A, Carroll M. BCR-ABL kinase is dead; long live the CML stem cell. J Clin Invest. 2011;121(1):22\u20135.","journal-title":"J Clin Invest"},{"issue":"1","key":"474_CR50","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","volume":"121","author":"AS Corbin","year":"2011","unstructured":"Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011;121(1):396\u2013409.","journal-title":"J Clin Invest"},{"issue":"14","key":"474_CR51","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1182\/blood-2015-05-646489","volume":"126","author":"W Wang","year":"2015","unstructured":"Wang W, Cortes JE, Lin P, Beaty MW, Ai D, Amin HM, et al. Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. Blood. 2015;126(14):1699\u2013706.","journal-title":"Blood"},{"issue":"3","key":"474_CR52","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/leu.2016.231","volume":"31","author":"Z Chen","year":"2017","unstructured":"\u2022\u2022 Chen Z, et al. Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia. 2017;31(3):585\u201392 Demonstration of changes in ACA landscape, prognostic impact of ACAs, and relationship between ACAs in CML-BP in TKI era.","journal-title":"Leukemia"},{"issue":"13","key":"474_CR53","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jnci\/djn188","volume":"100","author":"J Wu","year":"2008","unstructured":"Wu J, Meng F, Kong LY, Peng Z, Ying Y, Bornmann WG, et al. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst. 2008;100(13):926\u201339.","journal-title":"J Natl Cancer Inst"},{"key":"474_CR54","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1756-8722-4-6","volume":"4","author":"H Quentmeier","year":"2011","unstructured":"Quentmeier H, Eberth S, Romani J, Zaborski M, Drexler HG. BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance. J Hematol Oncol. 2011;4:6.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"474_CR55","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1182\/blood-2010-07-294330","volume":"117","author":"A Haouala","year":"2011","unstructured":"Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011;117(8):e75\u201387.","journal-title":"Blood"},{"issue":"12","key":"474_CR56","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","volume":"110","author":"DL White","year":"2007","unstructured":"White DL, Saunders VA, Dang P, Engler J, Venables A, Zrim S, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood. 2007;110(12):4064\u201372.","journal-title":"Blood"},{"key":"474_CR57","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed","author":"SH Swerdlow","year":"2017","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Switzerland: WHO Press; 2017."},{"issue":"22","key":"474_CR58","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood-2016-01-690230","volume":"127","author":"W Wang","year":"2016","unstructured":"\u2022 Wang W, et al. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 2016;127(22):2742\u201350 Stratification of CML patients based on ACA-associated patient survival in TKI era.","journal-title":"Blood"},{"issue":"26","key":"474_CR59","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1182\/bloodadvances.2017011858","volume":"1","author":"Z Gong","year":"2017","unstructured":"\u2022\u2022 Gong Z, et al. Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy. Blood Adv. 2017;1(26):2541\u201352 Four-tier stratification of CML based on ACA-associated risk of blastic transformation.","journal-title":"Blood Adv"},{"issue":"7","key":"474_CR60","first-page":"1134","volume":"10","author":"B Johansson","year":"1996","unstructured":"Johansson B, Fioretos T, Billstr\u00f6m R, Mitelman F. Aberrant cytogenetic evolution pattern of Philadelphia-positive chronic myeloid leukemia treated with interferon-alpha. Leukemia. 1996;10(7):1134\u20138.","journal-title":"Leukemia"},{"key":"474_CR61","unstructured":"Mitelman F, Johansson B, Mertens F. https:\/\/cgap.nci.nih.gov\/Chromosomes\/Mitelman . 2001. Accessed 1 Aug 2018."},{"issue":"6","key":"474_CR62","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1182\/blood.V86.6.2371.bloodjournal8662371","volume":"86","author":"A Gaiger","year":"1995","unstructured":"Gaiger A, Henn T, H\u00f6rth E, Geissler K, Mitterbauer G, Maier-Dobersberger T, et al. Increase of BCR-ABL chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood. 1995;86(6):2371\u20138.","journal-title":"Blood"},{"issue":"11","key":"474_CR63","first-page":"3048","volume":"51","author":"JQ Guo","year":"1991","unstructured":"Guo JQ, Wang JY, Arlinghaus RB. Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients. Cancer Res. 1991;51(11):3048\u201351.","journal-title":"Cancer Res"},{"issue":"42","key":"474_CR64","doi-asserted-by":"crossref","first-page":"6432","DOI":"10.1038\/sj.onc.1208796","volume":"24","author":"DJ Barnes","year":"2005","unstructured":"Barnes DJ, Schultheis B, Adedeji S, Melo JV. Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia. Oncogene. 2005;24(42):6432\u201340.","journal-title":"Oncogene"},{"issue":"3","key":"474_CR65","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.onc.1201490","volume":"16","author":"N Cambier","year":"1998","unstructured":"Cambier N, Chopra R, Strasser A, Metcalf D, Elefanty AG. BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner. Oncogene. 1998;16(3):335\u201348.","journal-title":"Oncogene"},{"issue":"3","key":"474_CR66","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/leu.2010.298","volume":"25","author":"V Grossmann","year":"2011","unstructured":"Grossmann V, Kohlmann A, Zenger M, Schindela S, Eder C, Weissmann S, et al. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia. 2011;25(3):557\u201360.","journal-title":"Leukemia"},{"issue":"6","key":"474_CR67","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2005-09-3732","volume":"107","author":"M Notari","year":"2006","unstructured":"Notari M, Neviani P, Santhanam R, Blaser BW, Chang JS, Galietta A, et al. A MAPK\/HNRPK pathway controls BCR\/ABL oncogenic potential by regulating MYC mRNA translation. Blood. 2006;107(6):2507\u201316.","journal-title":"Blood"},{"issue":"10","key":"474_CR68","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0145-2126(98)00097-6","volume":"22","author":"BA Jennings","year":"1998","unstructured":"Jennings BA, Mills KI. c-myc locus amplification and the acquisition of trisomy 8 in the evolution of chronic myeloid leukaemia. Leuk Res. 1998;22(10):899\u2013903.","journal-title":"Leuk Res"},{"issue":"7","key":"474_CR69","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","volume":"351","author":"CH Jamieson","year":"2004","unstructured":"Jamieson CH, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004;351(7):657\u201367.","journal-title":"N Engl J Med"},{"issue":"8","key":"474_CR70","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","volume":"103","author":"JP Radich","year":"2006","unstructured":"Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2006;103(8):2794\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"474_CR71","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1073\/pnas.0711824105","volume":"105","author":"SJ Zhang","year":"2008","unstructured":"Zhang SJ, Ma LY, Huang QH, Li G, Gu BW, Gao XD, et al. Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2008;105(6):2076\u201381.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"474_CR72","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood-2012-03-380147","volume":"120","author":"R Hehlmann","year":"2012","unstructured":"Hehlmann R. How I treat CML blast crisis. Blood. 2012;120(4):737\u201347.","journal-title":"Blood"},{"issue":"8","key":"474_CR73","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1182\/blood.V85.8.2013.bloodjournal8582013","volume":"85","author":"H Sill","year":"1995","unstructured":"Sill H, Goldman JM, Cross NC. Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood. 1995;85(8):2013\u20136.","journal-title":"Blood"},{"issue":"7191","key":"474_CR74","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature06866","volume":"453","author":"CG Mullighan","year":"2008","unstructured":"Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008;453(7191):110\u20134.","journal-title":"Nature"},{"issue":"3","key":"474_CR75","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1080\/10428194.2016.1204655","volume":"58","author":"Y Yin","year":"2017","unstructured":"Yin Y, Li J, Yan W, Cheng Z, Sun N, Zhang G. CEBPA mutation in a case of chronic myeloid leukemia presenting in myeloid blast crisis. Leuk Lymphoma. 2017;58(3):708\u201310.","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"474_CR76","doi-asserted-by":"crossref","first-page":"7622","DOI":"10.1073\/pnas.102583199","volume":"99","author":"AB Dash","year":"2002","unstructured":"Dash AB, Williams IR, Kutok JL, Tomasson MH, Anastasiadou E, Lindahl K, et al. A murine model of CML blast crisis induced by cooperation between BCR\/ABL and NUP98\/HOXA9. Proc Natl Acad Sci U S A. 2002;99(11):7622\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"474_CR77","first-page":"2728","volume":"81","author":"G Nucifora","year":"1993","unstructured":"Nucifora G, Birn DJ, Espinosa R 3rd, Erickson P, LeBeau M, Roulston D, et al. Involvement of the AML1 gene in the t(3;21) in therapy-related leukemia and in chronic myeloid leukemia in blast crisis. Blood. 1993;81(10):2728\u201334.","journal-title":"Blood"},{"key":"474_CR78","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1755-8166-7-42","volume":"7","author":"D Giacomo Di","year":"2014","unstructured":"Di Giacomo D, et al. Blast crisis Ph+ chronic myeloid leukemia with NUP98\/HOXA13 up-regulating MSI2. Mol Cytogenet. 2014;7:42.","journal-title":"Mol Cytogenet"},{"issue":"4","key":"474_CR79","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/scbi.2001.0387","volume":"11","author":"PJ Shteper","year":"2001","unstructured":"Shteper PJ, Ben-Yehuda D. Molecular evolution of chronic myeloid leukaemia. Semin Cancer Biol. 2001;11(4):313\u201323.","journal-title":"Semin Cancer Biol"},{"issue":"9","key":"474_CR80","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2016.143","volume":"30","author":"G Heller","year":"2016","unstructured":"Heller G, Topakian T, Altenberger C, Cerny-Reiterer S, Herndlhofer S, Ziegler B, et al. Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia. Leukemia. 2016;30(9):1861\u20138.","journal-title":"Leukemia"},{"issue":"7","key":"474_CR81","doi-asserted-by":"crossref","first-page":"e22110","DOI":"10.1371\/journal.pone.0022110","volume":"6","author":"J Jelinek","year":"2011","unstructured":"Jelinek J, Gharibyan V, Estecio MRH, Kondo K, He R, Chung W, et al. Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia. PLoS One. 2011;6(7):e22110.","journal-title":"PLoS One"},{"issue":"6","key":"474_CR82","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1182\/blood.V93.6.2075.406k29_2075_2080","volume":"93","author":"JP Issa","year":"1999","unstructured":"Issa JP, Kantarjian H, Mohan A, O'Brien S, Cortes J, Pierce S, et al. Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance. Blood. 1999;93(6):2075\u201380.","journal-title":"Blood"},{"issue":"1","key":"474_CR83","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2016-04-708560","volume":"129","author":"T Kim","year":"2017","unstructured":"Kim T, Tyndel MS, Kim HJ, Ahn JS, Choi SH, Park HJ, et al. Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy. Blood. 2017;129(1):38\u201347.","journal-title":"Blood"},{"issue":"8","key":"474_CR84","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/sj.leu.2403399","volume":"18","author":"C Terre","year":"2004","unstructured":"Terre C, et al. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia. 2004;18(8):1340\u20136.","journal-title":"Leukemia"},{"issue":"3","key":"474_CR85","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/sj.leu.2402848","volume":"17","author":"ME O'Dwyer","year":"2003","unstructured":"O'Dwyer ME, Gatter KM, Loriaux M, Druker BJ, Olson SB, Magenis RE, et al. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia. 2003;17(3):481\u20137.","journal-title":"Leukemia"},{"issue":"8","key":"474_CR86","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1182\/blood-2007-01-070045","volume":"110","author":"E Jabbour","year":"2007","unstructured":"Jabbour E, Kantarjian HM, Abruzzo LV, O'Brien S, Garcia-Manero G, Verstovsek S, et al. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 2007;110(8):2991\u20135.","journal-title":"Blood"},{"issue":"9","key":"474_CR87","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/cncr.11729","volume":"98","author":"J Medina","year":"2003","unstructured":"Medina J, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Giles F, et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer. 2003;98(9):1905\u201311.","journal-title":"Cancer"},{"issue":"7","key":"474_CR88","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/cncr.22936","volume":"110","author":"MW Deininger","year":"2007","unstructured":"Deininger MW, Cortes J, Paquette R, Park B, Hochhaus A, Baccarani M, et al. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells. Cancer. 2007;110(7):1509\u201319.","journal-title":"Cancer"},{"issue":"8","key":"474_CR89","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1182\/blood-2006-04-017400","volume":"108","author":"C Kovitz","year":"2006","unstructured":"Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo LV, Cortes J. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood. 2006;108(8):2811\u20133.","journal-title":"Blood"},{"issue":"1","key":"474_CR90","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cancergencyto.2010.08.017","volume":"204","author":"MJ Groves","year":"2011","unstructured":"Groves MJ, Sales M, Baker L, Griffiths M, Pratt N, Tauro S. Factors influencing a second myeloid malignancy in patients with Philadelphia-negative \u22127 or del(7q) clones during tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Cancer Genet. 2011;204(1):39\u201344.","journal-title":"Cancer Genet"},{"key":"474_CR91","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41379-018-0014-x","volume":"31","author":"H Kurt","year":"2018","unstructured":"\u2022 Kurt H, Zheng L, Kantarjian HM, Tang G, Ravandi-Kashani F, Garcia-Manero G, et al. Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome. Mod Pathol. 2018. Comprehensive study of emergence of secondary Ph and its significance.;31:1141\u201354.","journal-title":"Mod Pathol"},{"issue":"6","key":"474_CR92","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1111\/ijlh.12398","volume":"37","author":"Z Chen","year":"2015","unstructured":"Chen Z, Wang W, Verstovsek S, Cortes JE, Medeiros LJ, Hu S. Chronic myelogenous leukemia in patients with MPL or JAK2 mutation-positive myeloproliferative neoplasm. Int J Lab Hematol. 2015;37(6):e150\u20132.","journal-title":"Int J Lab Hematol"},{"issue":"5","key":"474_CR93","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/modpathol.2017.182","volume":"31","author":"CR Soderquist","year":"2018","unstructured":"Soderquist CR, Ewalt MD, Czuchlewski DR, Geyer JT, Rogers HJ, Hsi ED, et al. Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group. Mod Pathol. 2018;31(5):690\u2013704.","journal-title":"Mod Pathol"},{"issue":"5","key":"474_CR94","doi-asserted-by":"crossref","first-page":"E25","DOI":"10.3816\/CLM.2009.n.080","volume":"9","author":"SR Pingali","year":"2009","unstructured":"Pingali SR, et al. Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation. Clin Lymphoma Myeloma. 2009;9(5):E25\u20139.","journal-title":"Clin Lymphoma Myeloma"},{"issue":"11","key":"474_CR95","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.5858\/2007-131-1719-TOPVTC","volume":"131","author":"I Mirza","year":"2007","unstructured":"Mirza I, Frantz C, Clarke G, Voth AJ, Turner R. Transformation of polycythemia vera to chronic myelogenous leukemia. Arch Pathol Lab Med. 2007;131(11):1719\u201324.","journal-title":"Arch Pathol Lab Med"},{"issue":"4","key":"474_CR96","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/ejh.12343","volume":"93","author":"H Shimizu","year":"2014","unstructured":"Shimizu H, Yokohama A, Hatsumi N, Takada S, Handa H, Sakura T, et al. Philadelphia chromosome-positive mixed phenotype acute leukemia in the imatinib era. Eur J Haematol. 2014;93(4):297\u2013301.","journal-title":"Eur J Haematol"},{"issue":"5","key":"474_CR97","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.bjhh.2014.07.016","volume":"36","author":"I Franca Azevedo de","year":"2014","unstructured":"de Franca Azevedo I, et al. Frequency of p190 and p210 BCR-ABL rearrangements and survival in Brazilian adult patients with acute lymphoblastic leukemia. Rev Bras Hematol Hemoter. 2014;36(5):351\u20135.","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"17","key":"474_CR98","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1002\/cncr.25978","volume":"117","author":"J Jaso","year":"2011","unstructured":"Jaso J, Thomas DA, Cunningham K, Jorgensen JL, Kantarjian HM, Medeiros LJ, et al. Prognostic significance of immunophenotypic and karyotypic features of Philadelphia positive B-lymphoblastic leukemia in the era of tyrosine kinase inhibitors. Cancer. 2011;117(17):4009\u201317.","journal-title":"Cancer"},{"issue":"Suppl 1","key":"474_CR99","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s12288-013-0314-8","volume":"30","author":"SP Verrma","year":"2014","unstructured":"Verrma SP, Dutta TK, Vinod KV, Dubashi B, Ariga KK. Philadelphia chromosome positive pre-T cell acute lymphoblastic leukemia: a rare case report and short review. Indian J Hematol Blood Transfus. 2014;30(Suppl 1):177\u20139.","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"4","key":"474_CR100","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1309\/B4NVER1AJJ84CTUU","volume":"127","author":"CP Soupir","year":"2007","unstructured":"Soupir CP, Vergilio JA, Cin PD, Muzikansky A, Kantarjian H, Jones D, et al. Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis. Am J Clin Pathol. 2007;127(4):642\u201350.","journal-title":"Am J Clin Pathol"},{"key":"474_CR101","doi-asserted-by":"crossref","unstructured":"Konopleva M, et al. Molecular biology and cytogenetics of chronic myeloid leukemia. In: P.H. Wiemik, J.P. Dutcher, and M.A. Gertz, eds. Neoplastic Disease of the Blood. Springer. 2018:29-47.","DOI":"10.1007\/978-3-319-64263-5_4"},{"issue":"1","key":"474_CR102","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.hemonc.2014.09.002","volume":"8","author":"E Reboursiere","year":"2015","unstructured":"Reboursiere E, Chantepie S, Gac AC, Reman O. Rare but authentic Philadelphia-positive acute myeloblastic leukemia: two case reports and a literature review of characteristics, treatment and outcome. Hematol Oncol Stem Cell Ther. 2015;8(1):28\u201333.","journal-title":"Hematol Oncol Stem Cell Ther"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-018-0474-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-018-0474-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-018-0474-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T20:24:40Z","timestamp":1662323080000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-018-0474-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,29]]},"references-count":102,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["474"],"URL":"https:\/\/doi.org\/10.1007\/s11899-018-0474-6","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,29]]},"assertion":[{"value":"29 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}